Although ALK-rearranged lung cancers make up only 5% to 7% of all NSCLC cases, they have demonstrated an impressive responsiveness to the ALK tyrosine kinase inhibitor, crizotinib, and represent a therapeutically important subcategory. Here, ALK is linked to non-small cell lung carcinoma.